Preliminary Clinical Evidence Submission
Early trial results are gathered to support a breakthrough request.
- Phase 1/2: Evidence type (placeholder metric)
- Preliminary: Endpoint signal (placeholder metric)
- Existing therapy: Comparator (placeholder metric)
- In progress: Sponsor readiness (placeholder metric)
Building the evidence package
Short placeholder describing early data compilation for the filing.
Breakthrough Designation Request
A formal request is filed with the FDA for expedited review status.
- BTD Request: Filing type (placeholder metric)
- 60 days: Review clock (placeholder metric)
- Unmet need: Criteria cited (placeholder metric)
- Pre-request: Sponsor meetings (placeholder metric)
Filing the request
Short placeholder describing the designation request submission.
FDA Designation Granted
The FDA grants breakthrough therapy status to the psychedelic candidate.
- Granted: Outcome (placeholder metric)
- Fast-track: Unlocked benefit (placeholder metric)
- Senior staff: Agency contact (placeholder metric)
- Announced: Public notice (placeholder metric)
What designation unlocks
Short placeholder describing benefits of the granted status.
Intensive FDA Guidance Meetings
Frequent agency meetings shape trial design and endpoints.
- Frequent: Meeting cadence (placeholder metric)
- Trial design: Topics (placeholder metric)
- Enabled: Rolling review (placeholder metric)
- Senior mgmt: Agency involvement (placeholder metric)
Guidance meeting cadence
Short placeholder describing the intensive meeting schedule.
Accelerated Trial Timeline
Phase 2 and 3 trials proceed on a compressed regulatory schedule.
- Compressed: Phase 2/3 (placeholder metric)
- Rolling: Review type (placeholder metric)
- Years: Time saved (placeholder metric)
- Accelerated: Approval path (placeholder metric)
Compressed trial execution
Short placeholder describing the accelerated timeline outcome.
Short placeholder highlight summarizing the overall pathway benefit.